Very recently, Romee’s lab showed that arming CIML NK cells with TCR-like CAR against intracellular neoepitope nucleophosphmin-1 (NPM1) improves anti-AML responses and could be considered as a treatment for NPM1c-mutated HLA-A2+ AML patients (113). This evidence concerns the gene NPM1 and acute myeloid leukemia.